Korsana Biosciences, Inc. (KRSA)
31.05
+0.62
(+2.04%)
USD |
NASDAQ |
Nov 06, 16:00
31.42
+0.37
(+1.19%)
After-Hours: 20:00
Korsana Biosciences Research and Development Expense (Annual) : 0.959M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 0.959M |
| December 31, 2024 | 0.286M |
| December 31, 2023 | 1.515M |
| December 31, 2022 | 5.979M |
| December 31, 2021 | 37.64M |
| Date | Value |
|---|---|
| December 31, 2020 | 56.41M |
| December 31, 2019 | 95.14M |
| December 31, 2018 | 87.72M |
| December 31, 2017 | 78.80M |
| December 31, 2016 | 50.90M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Q32 Bio, Inc. | 19.16M |
| IRulya Therapeutics, Inc. | 35.38M |
| Climb Bio, Inc. | 46.62M |
| PepGen Inc. | 69.65M |
| Bridgebio Oncology Therapeutics, Inc. | 121.20M |